Pulmonary hypertension (PH) describes heterogeneous population of patients with a mean
pulmonary arterial pressure> 20 mm Hg. Rarely, PH presents as a primary disorder but is …

Pulmonary arterial hypertension (PAH) is caused by functional and structural changes in the
pulmonary vasculature, leading to increased pulmonary vascular resistance. The process of …

Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology. Vasoconstriction,
remodeling of the pulmonary vessel wall, and thrombosis contribute to increased pulmonary …

Chronic hypoxic exposure induces changes in the structure of pulmonary arteries, as well as
in the biochemical and functional phenotypes of each of the vascular cell types, from the …

Inflammatory processes are prominent in various types of human and experimental
pulmonary hypertension (PH) and are increasingly recognized as major pathogenic …

Recent clinical and experimental studies are redefining the cellular and molecular bases of
pulmonary arterial hypertension (PAH). The genetic abnormalities first identified in …

Recent investigations have suggested that it might be possible to reverse the pathology of
pulmonary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal …

Pulmonary hypertension (PH) is a disorder that develops as a result of remodeling of the
pulmonary vasculature and is characterized by narrowing/obliteration of small pulmonary …

Pulmonary arterial hypertension (PAH) is a complex disease that causes significant
morbidity and mortality and is clinically characterized by an increase in pulmonary vascular …

We have witnessed significant advances in the management of pulmonary arterial
hypertension (PAH)(1), a rare and severe condition characterized by intense pulmonary …